Growblox Sciences has filed the first of several likely patent applications for cannabis-based compounds developed by Growblox Life Sciences, its wholly owned subsidiary.
Articles by Ana de Barros, PhD
The Michael J. Fox Foundation (MJFF) has awarded a research grant to Asceneuron to develop small molecules with the potential to…
Great Lakes NeuroTech (GLNT) announced that it will partner with UCB to develop quantitative tools that will help Parkison’s…
A new device that may improve the autonomy and quality of life of patients with Parkinson’s disease will be tested…
NeuroDerm has started enrolling Parkinson’s disease (PD) patients in iNDiGO, a Phase 3 clinical trial evaluating the effectiveness of ND0612L, the company’s…
The nonprofit Parkinson’s Resources of Oregon (PRO) will unveil a series of Parkinson’s Ready training for the Portland Police Department,…
Changes in the retina of the eye may reveal the presence of Parkinson’s disease before brain changes and early symptoms appear,…
Parkinson’s disease patients in Europe will soon have to access a new treatment option for their disease, after the European…
Ann Johnson, a retired veterinarian diagnosed with Parkinson’s disease (PD) almost a decade ago, usually travels 130 miles from Champaign to Chicago…
Cynapsus Therapeutics recently provided an update on APL-130277, its sublingual formulation of apomorphine hydrochloride or apomorphine. Apomorphine injection is the…